| Drug Name |
Caspofungin |
| Drug ID |
BADD_D00376 |
| Description |
Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall. |
| Indications and Usage |
For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies. |
| Marketing Status |
approved |
| ATC Code |
J02AX04 |
| DrugBank ID |
DB00520
|
| KEGG ID |
D07626
|
| MeSH ID |
D000077336
|
| PubChem ID |
2826718
|
| TTD Drug ID |
D00ZCN
|
| NDC Product Code |
Not Available |
| UNII |
F0XDI6ZL63
|
| Synonyms |
Caspofungin | Cancidas | MK 0991 | MK-0991 | MK0991 | Caspofungin MSD | L 743,872 | L-743,872 | L743,872 | L-743872 | L743872 | L 743872 | Caspofungin Acetate |
